EUCTR2007-007587-21-DK进行中（未招募）1 期
Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocytic leukaemia - CLL10
GCLLSG - Dept. of Internal Medicine I, University Hospital Cologne0 个研究点目标入组 550 人开始时间: 2009年8月31日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 550
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.18 years of age or older.
- •2.Confirmed diagnosis of B-CLL.
- •3.Stage Binet C or stage Binet B and A requiring treatment.
- •Requiring treatment is defined as:
- •a) •Binet stage B or A plus at least one of the following signs or symptoms:
- •-B symptoms (night sweats, weight loss ? 10% within the previous 6 months, fevers > 38°C or 100.4°F for ? 2 weeks without evidence of infection) or constitutional symptoms (fatigue)
- •-progressive lymphocytosis (lymphocytosis is defined as peripheral lymphocyte count > 5x109/l) (increase > 50% over a 2-month period or doubling of peripheral lymphocyte count < 6 months)
- •-evidence of progressive marrow failure as manifested by the development / worsening of anemia and/or thrombocytopenia
- •-massive, progressive or painful splenomegaly or hypersplenism
- •-massive lymph nodes or lymph node clusters (> 10 cm in longest diameter)or progressive or symptomatic lymphadenopathy
- •4.World Health Organization performance status of 0-2.
- •5.Life expectancy> 6 months.
- •6.Adequate liver function as indicated by a total bilirubin, AST, and ALT =2 the institutional ULN value, unless directly attributable to the patient’s tumor.
- •7.Willingness of fertile male and female patients to use an highlyeffective contraceptive method with a Pearl-Index < 1 (such as implants, injectables, oral contraceptives in combincation with an other contraceptive method, some IUDs, sexual abstinence or vasectomised partner) while on study treatment and for a minimum of six months following study therapy
- •8.Signed, written informed consent.
- •9.Patient is a) male b) female and ? 2 years after the onset of menopause c) female and < 2 years after the onset of menopause and has a negative serum pregnancy test one week prior treatment.
- •10.Negative serological Hepatitis B test, negative testing of Hepatitis C RNA, negative HIV test within 6 weeks prior to registration.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.CIRS-Score > 6
- •2.Patients with a 17p deletion detected by FISH (these patients will be treated within the CLL2O or CLL2L protocol of the GCLLSG)
- •3.Creatinine clearance <70ml/min calculated according to the modified formula of Cockcroft and Gault or directly measured after 24h-urine collection.
- •4.Any prior chemotherapy and/or radiotherapy and/or immunotherapy, except for prednisolone treatment administered due to very high lymphocyte counts immediately before first FCR or BR treatment.
- •5.Patients who have progressed with more aggressive B-cell cancers such as Richter’s syndrome.
- •6.Active secondary malignancy requiring treatment (except basal cell carcinoma or malignant tumour curatively treated by surgery).
- •7.CIRS-Score > 6 or a single score of 4 for one organ category.
- •8.Patients with a 17p deletion detected by FISH (these patients will be treated within the CLL2O or CLL2L protocol of the GCLLSG)
- •9.Creatinine clearance <70ml/min calculated according to the modified formula of Cockcroft and Gault or directly measured after 24h-urine collection. Creatinine Clearance is to be calculated only in patients with serum creatinine = 1.1 mg/dl
- •10.Any prior CLL-specific chemotherapy and/or radiotherapy and/or immunotherapy, except for prednisolone treatment administered due to very high lymphocyte counts immediately before first FCR or BR treatment.
- •11.Patients who have progressed with more aggressive B-cell cancers such as Richter’s syndrome.
- •12.Active secondary malignancy requiring treatment (except basal cell carcinoma or malignant tumour curatively treated by surgery or successfully treated secondary malignancies in complete remission more than 5 years before enrollment ).
- •13.Participation in any other clinical trial
研究者
相似试验
进行中（未招募）
1 期
Patients who suffer from chronic lymphocytic leukemia and have not received any chemotherapy so far will be treated with fludarabine, cyclophosphamide and rituximab (FCR) or bendamustine and rituximab (BR)EUCTR2007-007587-21-ATniversity of Cologne, Sponsor-Quality Management550
进行中（未招募）
1 期
Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocytic leukemiaEUCTR2007-007587-21-DEniversity of Cologne550
进行中（未招募）
1 期
Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia - CLL10patients (age 18 years or older) with chronic lymphocytic leukemia: Stage Binet C or stage Binet B and A requiring treatmentMedDRA version: 14.0Level: LLTClassification code 10009310Term: CLLSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-007587-21-CZGCLLSG - Dept. of Internal Medicine I, University Hospital Cologne550
进行中（未招募）
不适用
Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia.EUCTR2004-002787-15-ITROCHE817
进行中（未招募）
不适用
Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia.EUCTR2004-002787-15-CZF. Hoffmann-La Roche Ltd817